| Biomarker ID | 897 |
| PMID | 22496929 |
| Year | 2012 |
| Biomarker | Macroglobulin α2 ; HP protein; CLU precursor; Fibronectin; Human Fcari bound To Iga1-Fc; α2-HS glycoprotein; Transthyretin precursor; Apolipoprotein E precursor; Igκ chain C region; |
| Biomarker Basis | Expression Based |
| Biomolecule | Protein |
| Source | Serum |
| Subjects | Humans |
| Regulation | Upregulated [>1.5 fold]: (Macroglobulin α2 ; HP protein; CLU precursor; ) Downregulated: [1.5 fold] (Fibronectin; Human Fcari bound To Iga1-Fc; α2-HS glycoprotein; Transthyretin precursor; Apolipoprotein E precursor; Igκ chain C region;) |
| Odds Ratio/Hazard Ratio/Relative Risk | NA |
| Effect on Pathways | NA |
| Experiment | Before and after androgen ablation therapy (AAT) |
| Type of Biomarker | Predictive |
| Cohort | 4 patients with advanced Pca were collected at the time of the initial diagnosis and 3 months after AAT. |
| Senstivity | NA |
| Specificity | NA |
| AUC | NA |
| Accuracy | NA |
| Level Of Significance | p<0.01 |
| Method Used | 2D-DiGE; MALDi ToF |
| Clinical | No |
| Remarks | NA |
| Clinical Trial Number | NA |
| Degree Of Validity | Validated on independent patient dataset |
| Technical Name | A2M, HP |